Jpmorgan Chase & CO Atara Biotherapeutics, Inc. Transaction History

Jpmorgan Chase & CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.44 - $1.22 $368,204 - $1.02 Million	-836,828 Reduced 38.25%	1,351,216 $932,000
Q4 2023 Feb 12, 2024	SELL	$0.23 - $1.74 $1.49 Million - $11.3 Million	-6,479,550 Reduced 74.76%	2,188,044 $1.12 Million
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.31 $1.34 Million - $2.19 Million	947,341 Added 12.27%	8,667,594 $12.8 Million
Q2 2023 Aug 11, 2023	BUY	$1.5 - $3.04 $96,726 - $196,031	64,484 Added 0.84%	7,720,253 $12.4 Million
Q1 2023 May 18, 2023	BUY	$2.8 - $5.46 $202,199 - $394,288	72,214 Added 0.95%	7,655,769 $22.2 Million
Q1 2023 May 11, 2023	BUY	$2.8 - $5.46 $235,535 - $459,295	84,120 Added 1.12%	7,583,555 $22 Million
Q4 2022 Feb 13, 2023	SELL	$2.85 - $5.18 $2.23 Million - $4.06 Million	-783,953 Reduced 9.46%	7,499,435 $24.6 Million
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $1.65 Million - $5.04 Million	-577,864 Reduced 6.52%	8,283,388 $31.3 Million
Q2 2022 Aug 11, 2022	BUY	$4.69 - $9.84 $3.15 Million - $6.61 Million	671,353 Added 8.2%	8,861,252 $69 Million
Q1 2022 May 11, 2022	BUY	$8.44 - $16.89 $6.52 Million - $13.1 Million	772,777 Added 10.42%	8,189,899 $76.1 Million
Q4 2021 Feb 10, 2022	SELL	$14.7 - $19.89 $8.8 Million - $11.9 Million	-598,695 Reduced 7.47%	7,417,122 $117 Million
Q3 2021 Nov 12, 2021	BUY	$11.99 - $17.9 $96.1 Million - $143 Million	8,015,817 New	8,015,817 $143 Million

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.